Vertex Pharmaceuticals, USA
Dr. Felicia Pagliuca is Vice President and Disease Area Executive, Type 1 Diabetes, at Vertex Pharmaceuticals, leading the team responsible for development of therapies for Type 1 diabetes. She also sits on the leadership team of Vertex Cell and Genetic Therapies. Dr. Pagliuca co-founded biotechnology company Semma Therapeutics and served as Vice President of Cell Biology R&D where she led the research and development of novel cell therapies for Type 1 diabetes. Semma was acquired by Vertex in 2019. Dr. Pagliuca received a B.S. from Duke University, and a Ph.D. from Cambridge University where she was a Marshall Scholar. She completed her postdoctoral fellowship with Dr. Douglas Melton at the Harvard Stem Cell Institute, where she was a co-inventor of stem cell derived islets.
Friday, July 12, 2024
8:15 AM – 9:45 AM CEST
Friday, July 12, 2024
1:30 PM – 3:00 PM CEST
STEM CELL-DERIVED, FULLY DIFFERENTIATED ISLET CELLS FOR TYPE 1 DIABETES
Friday, July 12, 2024
2:35 PM – 2:55 PM CEST